Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).Douglas R. Adkins, Makoto Tahara, Peter Oppelt et al.|Journal of Clinical Oncology|2019Cited by 18
Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysisMakoto Tahara, Douglas Adkins, Jin Lin et al.|Annals of Oncology|2019Cited by 0